Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Brainstorm’s Alzheimer’s Key Opinion Leader Event

Brainstorm’s July 8, 2020 Key Opinion Leader (KOL) Webinar on the Company's Alzheimer's Disease (AD) Clinical Program.

Corresponding Presentation

Recent News
Sep 16, 2020

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has...

Sep 3, 2020

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...

Sep 2, 2020

NEW YORK, September 2, 2020 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment...

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds